Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Neuroendocrine Tumors 5Pheochromocytoma 2Paraganglioma 2Meningioma 2Medulloblastoma 2Glioma 2Ependymoma 2Small Cell Lung Carcinoma 1Sarcoma, Synovial 1Recurrence 1Osteosarcoma 1Neuroblastoma 1Neoplasms, Germ Cell and Embryonal 1Glioblastoma 1Gastro-enteropancreatic neuroendocrine tumor 1Extensive Stage Small Cell Lung Cancer 1Esthesioneuroblastoma, Olfactory 1Diffuse Intrinsic Pontine Glioma 1Central Nervous System Neoplasms 1Carcinoma, Merkel Cell 1Carcinoma 1Carcinoid Tumor 1Adrenal Gland Neoplasms 1Adrenal Cortex Neoplasms 1

Interventions

lutetium Lu 177 dotatate 1atezolizumab 1Paclitaxel 1Etoposide 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Extensive Stage Small Cell Lung Cancer × lutetium Lu 177 dotatate × Clear all
NCT05142696 2026-05-29

A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab

Novartis

Phase 1/2 Active not recruiting
24 enrolled
Thoracic

Extensive Stage Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡